Eton Pharmaceuticals Q2 2026: Revenue Nearly Doubles, Profitability Soars
ETON has more than doubled off its 52-week low of $14.27.
Summary
Eton Pharmaceuticals reported Q2 2026 revenue of $37.6 million, up 99% year-over-year, and net income of $11.6 million, a significant swing to profitability. The company also disclosed a new $40 million credit facility and the IMPAVIDO supply agreement.
Key Events · Earnings and Guidance · ETON
-
Revenue Nearly Doubles
Total net revenues for Q2 2026 were $37.6 million, a 99% increase from $18.9 million in Q2 2025, driven by strong sales of INCRELEX, GALZIN, and the addition of HEMANGEOL.
-
Profitability Achieved
Net income was $11.6 million for Q2 2026, compared to a net loss of $2.6 million in Q2 2025. Diluted EPS was $0.35, versus a loss of $0.10 per share.
-
Cash Flow Positive
Net cash from operating activities was $14.7 million for the first half of 2026, up from $10.0 million in the prior year period, reflecting strong collections and lower inventory purchases.
-
Credit Facility Expanded
The company amended its SWK credit agreement in April 2026, increasing the facility to $40 million and reducing the interest rate to SOFR plus 6.55%, with an interest-only period extended to November 2026.
Analysis · ETON · Life Sciences
Eton Pharmaceuticals delivered a blowout Q2 2026, with total net revenues of $37.6 million, up 99% year-over-year, and net income of $11.6 million, a swing from a loss of $2.6 million in the prior year. The company's rare disease portfolio is scaling rapidly, driven by INCRELEX, GALZIN, and the addition of HEMANGEOL. The 10-Q also reveals a strengthened balance sheet with $26.8 million in cash and a new $40 million credit facility, providing ample runway for continued product launches and acquisitions.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 37.9% of the 895 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ETON was trading at $51.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $14.27 to $50.18. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.